Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Treatment and Prevention of Age-Related Macular Degeneration and Other Eye-Related Diseases

Posted Oct 31 2008 5:00pm

Description of Invention:
The retinal pigment epithelium (RPE) plays a significant role in regulating the microenvironment around the photoreceptors in the distal retina, where the events of phototransduction take place.

Expression profiling of microRNA (miRNAs) in RPE and the adjacent retina and choroid was used to identify six miRNAs enriched in RPE. The potential use of anti-miRNAs specifically directed against miRNA 204 and miRNA 211 to prevent epithelial cell differentiation, proliferation and migration is disclosed. The miRNA 204 and miRNA 211 play a critical role in the control transepithelial electrical resistance. This technology further describes the significance of miRNAs in regulating junctional complexes in epithelial cells.

The claims in the pending patent application are directed towards methods and compositions containing anti-miRNAs or miRNA mimics for preventing or treating detrimental epithelial cell proliferation or loss of epithelial cell differentiation.

Applications:
  • Treatment and prevention of age-related macular degeneration (AMD) and proliferative vitreal retinopathy.
  • Treatment and prevention of neovascular diseases and carcinoma.


Development Status:
Preclinical animal model studies and gene knockout studies are in progress.

Inventors:
Fei Wang (NEI)
Sheldon S Miller (NEI)


Patent Status:
HHS, Reference No. E-056-2008/0
PCT, Application No. PCT/US2009/55000 filed 26 Aug 2009


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Eye Institute, Section on Epithelial and Retinal Physiology and Disease, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of RPE-specific micro RNAs or anti-miRNAs or miRNA mimics for the treatment and prevention of age-related macular degeneration (AMD) and proliferative vitreal retinopathy, and more generally for preventing or treating detrimental epithelial cell proliferation or loss of epithelial cell differentiation, e.g., in the treatment and prevention of neovascular diseases and carcinoma.. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Ophthalmology
Ophthalmology - Therapeutics



For Additional Information Please Contact:
Suryanarayana Vepa Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vepas@mail.nih.gov
Phone: 301-435-5020
Fax: 301-402-0220


Ref No: 1846

Updated: 11/2008

Post a comment
Write a comment: